Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5953982 | Chest | 2015 | 7 Pages |
Abstract
We present, to our knowledge, the largest study examining clinical outcomes related to IPC placement in patients with hematologic malignancy. An overall 7.7% infection risk and 2.2% mortality were identified, similar to previously reported studies, despite the significant immunosuppression and pancytopenia often present in this population. IPC placement appears to remain a reasonable clinical option for patients with recurrent pleural effusions related to hematologic malignancy.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Christopher R. DO, Hans J. MD, Joseph H. MD, Fabien MD, FCCP, Momen MD, MBA, FCCP, Philip J. MD, Jamie MD, Daniel MD, FCCP, A. Christine MD, FCCP, Samira MD, FCCP, Jed A. MD, FCCP, Candice L. MD, David MD, FCCP, Ricardo BS, Bareng Aletta Sanny PhD,